Have questions about BPC-157 + TB-500 ?

Text us: 303-204-2469   720-499-6468

10 in stock

BPC-157 + TB-500

Recovery Compound

Quantity

Title

Discount

Buy 1

0%

Buy 2

3%

Buy 3

5%

Buy 4

10%

Research Use Only

These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.

What is the BPC-157 & TB-500 blend?

BPC-157 + TB-500 is a peptide combination that has gained attention in laboratory research. BPC-157 is a synthetic fragment derived from a gastric protein sequence, while TB-500 is a synthetic form of thymosin beta-4. Together, they are often studied in vitro for their roles in cellular response, angiogenesis, and cytoskeletal dynamics.

Frequently asked questions

Products from DTC Peptides do not include usage instructions, as they are strictly for in vitro research and prohibited by law for human or animal use. Misuse or unlawful application will result in permanent denial of service.
Each vial contains exactly what’s shown on the label. For example, a 10mg vial has exactly 10mg of lyophilized peptide. Researchers can divide it into smaller portions—like four 2.5mg measurements—but the total amount remains 10mg.
Peptides are supplied as lyophilized powder. They do not come reconstituted, and any extra supplies must be sourced separately for research applications.
In lyophilized powder form, peptides stay stable for up to 2 years. After reconstitution, it should be refrigerated and is generally stable for up to 2 months.

Made in the USA

Quality controlled from start to finish. No outsourcing.

Need Help?

Send us a message.

BPC-157 + TB-500 Overview

The BPC-157 + TB-500 blend combines two synthetic peptides studied for their regenerative properties. BPC-157 is known for its potential effects on cellular protection, structural repair, and inflammation modulation, while TB-500 (a fragment of Thymosin Beta-4) is associated with tissue healing, angiogenesis, and improved flexibility of muscle and connective tissue. Together, they may provide complementary support for recovery and repair in laboratory and animal models.

Goldstein A. et al. (2005).

History

The concept of the BPC-157 + TB-500 blend stems from parallel lines of peptide research tracing back to foundational discoveries in regenerative biology. BPC-157, deriving from a natural protein fragment in gastric tissue, was first synthesized to investigate its protective and reparative effects on gastrointestinal and musculoskeletal systems. Meanwhile, Thymosin β-4 (Tβ4)—and its synthetic fragment TB-500—originated from the discovery of thymosins in the 1960s by Allan L. Goldstein and colleagues, leading to interest in Tβ4’s role in wound healing and tissue regeneration.

Goldstein A. L., Hannappel E. et al. (2012).

BPC-157 Structure

CAS #: 137525-51-0

Molecular Formula: C₆₂H₉₈N₁₆O₂₂

Molecular Weight: 1419.556 g/mol

PubChem ID: 108101

TB-500 Structure

CAS #: 77591-33-4

Molecular Formula: C₆₂H₉₈N₁₆O₂₂

Molecular Weight: 1419.556 g/mol

PubChem ID: 108101

Research Findings

BPC-157 and TB-500 have been studied in structural, vascular, dermatological, and systemic models, with research exploring their effects on tendon-to-bone healing, collagen organization, angiogenesis, wound closure, and systemic protection. These findings highlight their roles in tissue support, vascular pathways, and recovery processes in preclinical settings.

Key Areas of Resarch:

• Structural: Tendon-to-bone, collagen, repair

• Vascular: Angiogenesis, nitric oxide, remodeling

• Dermatological: Wound closure, inflammation, epithelium

• Systemic: Gastrointestinal, survival, recovery

Together, these findings suggest broad experimental applications for BPC-157 and TB-500 across multiple biological pathways. Their combined influence on collagen synthesis, vascular support, inflammation, and systemic protection provides a versatile foundation for research into tissue repair, recovery, and regenerative biology.

Sikiric P. et al., Current Pharmaceutical Design, 2018

Text us, our dedicated team is here to help

Reach out and get a response within minutes.

You are not allowed because you are under 21.